Kornimate/medical-research-clean huggingface dataset:
non-interventional observational study of helical tomotherapy for oligometastatic colorectal cancer

Conditions: Colon Cancer; Rectal Cancer; Colorectal Cancer

Summary: patients with oligometastatic colorectal cancer (5 metastases or less) receive a combination of systemic treatment and often local treatment, such as surgery, radiofrequency ablation and more recently stereotactic body radiotherapy. the aim of this study is to register the results and side effects of stereotactic body radiotherapy (sbrt) by means of helical tomotherapy in the treatment of oligometastatic colorectal cancer. the trial has two cohorts. patients in cohort i get consolidation sbrt after best response on first line chemotherapy. patients in cohort ii get sbrt when there is progression under, or no indication for (further) chemotherapy. the primary endpoint is to evaluate the metabolic complete remission rate three months after the start of radiotherapy.


Eligibility criteria:
inclusion criteria: * patients with (residual) oligometastatic crc: ≤ 5 mets * primary tumor treated with curative intention (surgery, radiotherapy, chemoradiotherapy) * functional liver volume \> 1000cc if livermets, lung dlco \> 30% if lungmets. * no child b or c liver cirrhosis * no contra-indications for radiation of all metastatic crc (= no violation of constraints of organs at risk (oar)) * no mets from another carcinoma * age \> 18 years * who-ps ≤ 2

Keywords: oligometastatic disease colorectal cancer stereotactic body radiotherapy tomotherapy metabolic response stage iv
wearable devices empowering active health initiatives for high-risk stroke populations

Conditions: Hypertension; Diabetes; Atrial Fibrillation; Dyslipidemia; Smoking; Physical Inactivity; Obesity and Overweight

Summary: the purpose of this study is to evaluate the control effect of smart wearable devices on key risk factors in the high-risk populations for stroke

a randomized controlled study was conducted on the application of smart wearable devices in the intervention of high-risk populations for stroke, with a focus on whether the functions of smart wearable devices such as medication reminders, heart rate monitoring, and exercise reminders can effectively benefit the improvement of key risk factors for stroke, especially blood pressure, blood glucose, and blood lipids.

Eligibility criteria:
inclusion criteria: 1. diagnosed with hypertension; 2. diagnosed with diabetes; 3. diagnosed with atrial fibrillation; 4. smoking subjects; 5. physical inactive subjects； 6. obesity and overweight subjects; 7. must be able to use smart wearable devices. exclusion criteria: 1. diagnosed with malignancies; 2. diagnosed with psychiatric disorders; 3. diagnosed with cognitive impairment; 4. unable to operate smart wearable devices.
comparison of the perception of pain between orthodontic treatment with invisalign ® and treatment with brackets

Conditions: PAIN

Summary: this study aims to compare the pain experienced by patients undergoing orthodontic treatment with invisalign ® corrective aligners with that of patients undergoing orthodontic treatment with conventional braces. because the aligners are removable, nearly invisible and don't involve metal that can irritate teeth and gums, we are expecting less pain in the invisalign treatment and less affectation of the quality of life.

the aims of the study are to determine: the presence of pain, the magnitude of pain, the duration of pain, and the location of pain. the hypotheses of this study are: * treatment with invisalign ® aligners result in less pain than the braces * treatment with invisalign ® aligners result in less irritation to the soft tissues with braces * pain should increase each time the aligners are put in the mouse and decrease until disappearing on the third day. * the quality of life will be most affected by treatment with braces than with invisalign ®. * null hypothesis: there is no difference at all points between the two treatments.

Eligibility criteria:
inclusion criteria: * in permanent dentition; * age less than 30 years; * no medical contraindications or presence of systemic diseases (including nervous system disorders); * no missing teeth except the third molars; * orthodontic treatment without extraction. * relationship skeletal cl. i (or slightly cl. ii or cl. iii) * speak and understand french without help. exclusion criteria: lack of compliance with appointments. -

Keywords: pain orthodontic treatment invisalign
rate control efficacy in permanent atrial fibrillation

Conditions: Persistent Atrial Fibrillation

Summary: the investigators hypothesis is that in patients with permanent af lenient rate control is not inferior to strict rate control in terms of cardiovascular mortality, morbidity, neurohormonal activation, nyha class for heart failure, left ventricular function, left atrial size, quality of life and costs. lenient rate control is defined as a resting heart rate \<110 bpm.strict rate control is defined as a mean resting heart rate \< 80 beats per minute (bpm) and heart rate during minor exercise \< 110 bpm. patients will be seen after 1, 2, 3 months (for titration of rate control drugs) and thereafter yearly.

study objectives: 1. to show that lenient rate control is not inferior to strict rate control in terms of cardiovascular mortality and morbidity 2. to show that lenient rate control is not inferior to strict rate control in terms of all cause mortality, cardiovascular hospitalizations, nyha class for exercise tolerance, left ventricular function and left atrial size, quality of life, neurohormonal activation as measured by nt-probnp, hospitalization for heart failure, syncope, sustained ventricular tachycardia, appropriate shocks or anti-tachycardia pacing of icd for ventricular arrhythmias, cardiac arrest, and pacemaker implantations, stroke, systemic emboli, and bleeding, unstable angina pectoris and myocardial infarction, costs and renal function

Eligibility criteria:
inclusion criteria: * patients with a current episode of permanent af \< 12 months. * age \</= 80 years. * mean resting heart rate \> 80 beats per minute with or without rate control medication * oral anticoagulation (or aspirin if no risk factors for thromboembolic complications are present). exclusion criteria: * paroxysmal af * known contra-indications for either strict or lenient rate control (e.g. previous adverse effects on negative chronotropic drugs). * unstable heart failure defined as nyha iv heart failure and heart failure necessitating hospital admission \< 3 months before inclusion. * cardiac surgery \< 3 months. * any stroke. * current or foreseen pacemaker and/ or cardiac resynchronization therapy. * signs of sick sinus syndrome or av conduction disturbances (i.e. symptomatic bradycardia or asystole \> 3 seconds or escape rate \< 40 beats per minute in awake symptom-free patients). * untreated hyperthyroidism or \< 3 months euthyroidism. * inability to walk or bike.
risk assessment of proximal contact loss between implant-supported prostheses and adjacent teeth.

Conditions: Peri-Implantitis and Peri-implant Mucositis

Summary: in this study, we collected and analysed the review results of 100 patients over 18 years of age who received implant fixed restorations in the department of stomatology of the first hospital of nanjing, china. the aim was to investigate the incidence of loss of contact between implant restorations and adjacent teeth and its influencing factors. our findings may provide better insights for treatment planning and prevention of pcl.

food impaction is a common complication after implant-supported restorations. several studies have reported that more than 40%-66.9% of patients feel food impaction between the implant restoration and adjacent natural teeth. the most common cause of food impaction after implant restoration is the proximal contact loss(pcl), which has been reported to occur in 34% to 65% of cases. the location of pcl creates discomfort and leads to gingival inflammation and even peri-implant bone resorption, which ultimately leads to loosening of the implant. in our long-term clinical observation, not all final restorations suffer from pcl. the occurrence of pcl may be related to a number of factors such as age, gender, functional time, and so on. however, the literature addressing this issue is still limited. in this study, we collected and analysed the review results of selected patients who underwent implant-supported restorations in the first hospital of nanjing, china, to investigate the incidence of pcl between the implant restorations and the adjacent teeth adjacent , and the factors influencing it. our findings may provide better insights for treatment planning and prevention of pcl.

Eligibility criteria:
inclusion criteria: * (1) patients over the age of 18, can fully understand the nature of the proposed and be able to sign a consent form. * (2) patients who underwent dental implant surgery and delivered prostheses for more than 3 months in nanjing first hospital. exclusion criteria: * (1) the implant site or adjacent teeth were severely injured and the adjacent teeth were extracted; * (2) the same quadrant orthodontic or splint treatment; * (3) the prostheses have been removed due to failure or need further treatment; * (4) implant-supported prostheses in both mesial and distal sites; * (5) the adjacent teeth were directly or indirectly fixed with the implant-supported prosthesis; * (6) patients with missing clinical records of pd, pcr and bop. * (7) the prosthetic prosthesis with implant-supported prosthesis was delivered for less than 3 months in nanjing first hospital.

Keywords: food impaction proximal contact loss implant supported prosthesis dentition defect risk factors
the becoming of children with doose syndrome

Conditions: Doose Syndrome; Epileptic Syndromes; Learning Disabilities

Summary: doose syndrome is a rare epileptic syndrome that can lead to learning difficulties and a poor quality of life. the goal of this study is to evaluate the evolution of epilepsy and its consequences on cognitive development and learning issues in children with doose syndrome.

doose syndrome is a rare epileptic syndrome beginning between ages two and five, characterized by myoclonic-astatic seizures which can be associated with myoclonic seizures, astatic seizures, absences and generalized tonic-clonic seizures. these seizures can be difficult to treat effectively and may lead to learning difficulties. during this study, parents of children with doose syndrome will receive a questionnaire regarding learning disabilities, quality of life and epilepsy of their children.

Eligibility criteria:
inclusion criteria: * children with doose syndrome diagnosed between ages 1 and 6 * normal development until onset of seizures exclusion criteria: * unconfirmed diagnoses * abnormal diagnoses * abnormal psychomotor development before onset of seizures * cerebral mri abnormalities * other child epileptic syndromes

Keywords: doose syndrome epileptic syndromes learning disabilities
prediction of mortality after cied implantation (pm-cied)

Conditions: Heart Failure, Systolic; Sudden Cardiac Death

Summary: the study aims to develop and validate predictive models for the mortality of patients receiving cied (including crt and icd) implantation.

the study aims to develop and validate predictive models for the mortality of patients receiving cardiovascular implantable electronic devices (cied) \[including cardiac resynchronization therapy (crt) and implantable cardioverter defibrillator (icd)\] implantation, with traditional statistical analysis and machine learning algorithms.

Eligibility criteria:
inclusion criteria: * all patients who received implantation of crt/icd exclusion criteria: * patients who received generator placement of crt/icd
retroclavicular versus supraclavicular brachial plexus block for hand and forearm surgery

Conditions: Hand Injury

Summary: patients will be randomized to one of two groups: 1. supraclavicular group: supraclavicular brachial plexus block performed with the aid of ultrasound; 2. retroclavicular group: retroclavicular brachial plexus block performed with the aid of ultrasound.

the study will be proposed to all patients undergoing formarm or hand surgery under brachial plexus block. patients will be randomized to one of two groups the first group - supraclavicular group - will receive an ultrasound-guided brachial plexus block via the supraclavicular approach, by injection of 30 ml of a mixture of ropivacaine 0.5 % + mepivacaine 1 %. the second group - retroclavicular group - will receive an ultrasound-guided brachial plexus block via the retroclavicular approach, by injection of 30 ml of a mixture of ropivacaine 0.5 % + mepivacaine 1 %. primary outcome is success rate at 30 minutes after the injection defined as loss of sensation to pinprick in the forearm and hand. secondary outcomes are: needling time, time to first analgesic request, postoperative opioid consumption, pain scores at 12 and 24 hours postoperatively, block-related complications, and patient satisfaction.

Eligibility criteria:
inclusion criteria: * adult patients who undergo forearm or hand surgery under brachial plexus block. exclusion criteria: * history of allergic reaction to local anaesthetics * peripheral neuropathy * renal or hepatic insufficiency * coagulation disorders
tranexamic acid in pediatric undergoing proximal femoral osteotomies and/or acetabular osteotomy

Conditions: Intraoperative Blood Loss; Pediatric; Orthopedic Disorder

Summary: surgical hip reconstruction reduces the hip joint through soft tissue releases and osteotomies of the femur and/or pelvis. blood loss and subsequent blood transfusion are normal consequences of hip reconstruction.

the use of antifibrinolytics (afs) to limit blood loss peri-operatively has been popularized in certain subspecialties. afs have been studied extensively in adults undergoing various orthopedic procedures including spine and total joint arthroplasty, and have been proven to reduce blood loss and reduce the risk of blood transfusion. similarly, afs are used in pediatric patients undergoing cardiac surgery as well as craniofacial operations. tranexamic acid (txa) is a synthetic anti-fibrinolytic agent that works by reversibly blocking plasminogen and thereby promoting hemostasis through the prevention of fibrin degradation. current literature investigating the safety and effectiveness of txa in children undergoing orthopedic procedures is limited. we hypothesize that patients treated with txa will have reduced blood loss and transfusion requirements compared with those who did not receive txa.

Eligibility criteria:
inclusion criteria: * asa i - ii * scheduled for acetabular osteotomy and/or proximal femoral derotation osteotomies. exclusion criteria: * patient's guardian refusal to participate in the study. * children known to have pre-existing bleeding or coagulation disorders. * children with anemia; defined according to (who ) cutoffs as hb level\<11g/dl for girls and \<12g/dl for boys * history of epilepsy. * history of renal insufficiency or failure
standard vs mini-pcnl for the treatment of stone disease

Conditions: Urolithiasis; Kidney Stone; Kidney Calculi; Ureteral Calculi; Kidney Diseases

Summary: randomized comparison of patient outcomes following standard pcnl versus mini-pcnl.

this study is a randomized controlled trial which compares the operative outcomes and complications of mini-percutaneous nephrolithotomy (mini-pcnl) versus standard pcnl for renal stones. this study will be a multi-institutional, prospective randomized controlled clinical trial with patients who have already agreed to undergo pcnl. patients will be randomized at a 1:1 ratio to receive either standard pcnl or mini-pcnl, defined as tract sizes of 30 and 16.5 to 18 french respectively. patients will be asked to complete pre-operative, and post-operative quality of life questionnaires, and to allow collection of one additional vial of blood for measurement of factors associated with inflammation. the participating institutions are academic medical centers in the united states and canada that are part of the edge research consortium.

Eligibility criteria:
inclusion criteria: * patients planned for pcnl at participating institutions * age ≥ 18 years old * male and female patients * patients of all ethnic backgrounds * stone size 10-20mm patients must be capable of giving informed consent and must be capable and willing to enroll and participate fully with the study. exclusion criteria: * conversion to open procedure * multiple access tracts * anticoagulated or history of coagulopathy * preoperative ureteral stent or nephrostomy tube placement * technical problems/impossibility of localizing the stone on the day of intervention patients unable to give informed consent or unwilling to enroll or participate in the study will be excluded.

Keywords: percutaneous nephrolithotomy pcnl
influence of perioperative kidney function on postoperative outcome

Conditions: Renal Insufficiency; Acute Kidney Injury

Summary: this study investigates the influence of perioperative changes in serum creatinine on hospital length of stay and mortality.


Eligibility criteria:
inclusion criteria: * all patients anesthetized between january 2006 - june 2012 exclusion criteria: * end stage renal disease * pre-anesthesiologic need of renal replacement therapy * patients undergoing nephrectomy or kidney transplantation
comparison of regional block, wound infiltration and caudal block for pain management in children

Conditions: Inguinal Hernia

Summary: comparison of regional block, wound infiltration and caudal block for post operative pain management in participants undergoing inguinal herniotomy.

investigators are comparing three modalities (regional block, wound infiltration and caudal block), for post operative pain management in participants after inguinal herniotomy.

Eligibility criteria:
inclusion criteria: 1. •patients under 13 years of age 2. •inguinal hernia exclusion criteria: 1. •history of allergy to any drugs used in study documented on history. 2. •infection at the site of regional, caudal or local infiltration, documented on clinical examination. 3. •irreducible, obstructed or strangulated hernia, documented on clinical examination.
expanded access to trilaciclib for patients receiving chemotherapy for small cell lung cancer

Conditions: Myelosuppression Adult; Chemotherapeutic Toxicity; Small Cell Lung Cancer

Summary: the purpose of this expanded access protocol is to provide access to trilaciclib for chemotherapy-induced myelosuppression in patients receiving chemotherapy as a treatment for small cell lung cancer (sclc). patients will receive trilaciclib intravenously as a 30-minute infusion prior to chemotherapy dosing and on each day that chemotherapy is administered. supplementary to providing access to trilaciclib, this expanded access program will also capture real world data to help inform subsequent trilaciclib development. requests for access to trilaciclib will be managed by bionical emas. g1 therapeutics will review eligibility of, as well as complete a medical review of, each patient access request.


Eligibility criteria:
inclusion criteria: * patients who require treatment with either intravenous etoposide + platinum (carboplatin or cisplatin) ± an anti-pdl1 or anti-pd1 checkpoint inhibitor or intravenous topotecan * pathologically confirmed diagnosis of sclc * extensive-stage or limited-stage sclc; patients with limited-stage sclc receiving chemotherapy with concurrent radiation are not eligible. * age ≥ 18 years * ecog 0 to 2 * absolute neutrophil count (anc) ≥ 1.5 x 10\^9/l at time of initiation of therapy in this eap * platelet count ≥ 100 x 10\^9/l at time of initiation of therapy in this eap * glomerular filtration rate (gfr) of ≥ 20 ml/minute at time of initiation of therapy in this eap * total bilirubin ≤ 1.5x uln (upper limit normal) at time of initiation of therapy in this eap * ast or alt ≤ 2.5x uln (≤ 5x uln in the presence of liver metastases) at time of initiation of therapy in this eap * qtcf interval ≤ 450 msec (males) or ≤ 470 msec (females) at screening (confirmed on repeat). for patients with ventricular pacemakers, qtcf ≤ 500 msec * no personal or family history of long qt syndrome * female patient is not lactating or currently pregnant, or plans to become pregnant, while participating in this expanded access program * female patients of reproductive potential agree to use effective contraception while in the program and for at least 3 weeks after the last dose of trilaciclib * patient agrees not to participate in another expanded access program or clinical trial with an experimental treatment during participation in this eap * active clinical trial with trilaciclib is not available (or if available, it is not appropriate) for the patient exclusion criteria: * patients requiring treatment with oral etoposide or oral topotecan * patients outside of the united states

Keywords: lung cancer small cell lung carcinoma small cell lung cancer extensive stage small cell lung cancer limited stage small cell lung cancer metastatic chemotherapy-induced neutropenia chemotherapy-induced anemia cdk 4/6 inhibitor trilaciclib etoposide carboplatin cisplatin topotecan checkpoint inhibitor myelosuppression cyclin-dependent kinase 4/6 inhibitor myelopreservation real world data chemotherapy-induced myelosuppression